- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- 64Cu-DOTA-ECLIi, PET/CT
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 1,356
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HSP, Hereditary Spastic Paraplegia, Hereditary Spastic Paraparesis, Hereditary Spastic Paraplegia Type 50, Hereditary Spastic Paraplegia Type 47, Hereditary Spastic Paraplegia Type 51, Hereditary Spastic Paraplegia Type 52, SPG47, AP4B1, Neurogenetic Disorders, Neurodevelopmental Conditions, Movement Disorders, Gene Therapy
- Interventions
- BFB-101 (AAV9-CBh-AP4B1)
- Biological
- Lead sponsor
- BlackfinBio Ltd
- Industry
- Eligibility
- 12 Months to 60 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Biological · Device · Other
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Liver Dysfunction
- Interventions
- liver biopsy
- Procedure
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 5 more
- Conditions
- Breast Cancer
- Interventions
- laboratory biomarker analysis
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Female only
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 3
- States / cities
- Sioux City, Iowa
- Conditions
- Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
- Interventions
- Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 9 more
- Conditions
- Healthy, Sicca Syndrome, Sjögren's Syndrome
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
- Conditions
- Neoplasm Malignant, Breast Cancer, Lung Neoplasm Malignant, Gastric Cancer, Neoplasm
- Interventions
- SAR443216 IV, SAR443216 SC
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Head and Neck Cancer
- Interventions
- DACH polymer platinate AP5346, oxaliplatin, gene expression analysis, immunohistochemistry staining method, pharmacological study, biopsy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma
- Interventions
- oblimersen sodium, rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, biopsy, microarray analysis, immunohistochemistry staining method, gene expression analysis, cytogenetic analysis
- Biological · Drug · Procedure + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 2
- States / cities
- Grand Island, Nebraska • Omaha, Nebraska
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Interventions
- Decitabine, LBH589, Tamoxifen
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Refractory Cancer, Recurrent Cancer, Adult Solid Tumor, Neoplasms
- Interventions
- Not listed
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver
- Interventions
- LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
- Diagnostic Test
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Tulsa, Oklahoma • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, oxaliplatin, irinotecan hydrochloride, bevacizumab, cetuximab, capecitabine, mutation analysis, gene expression analysis, laboratory biomarker analysis, immunohistochemistry staining method, nucleic acid sequencing, protein expression analysis, polymerase chain reaction, DNA analysis
- Drug · Biological · Genetic + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cancer, Malignant Neoplasm
- Interventions
- Bioelectrical impedance Analysis (BIA), D3-Creatine Dilution (D3Cr), 6-Minute Walk Test (6MWT), Timed Up and Go (TUG), 30-second Sit-to-Stand (STS), Hand Grip Strength (GS), PBTL p16 expression, CT, MR and PET Imaging
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Stress, Psychological, Mental Health Impairment
- Interventions
- Advancing Adolescents
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 817 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Mesial Temporal Lobe Epilepsy
- Interventions
- AAV9-hSyn1-miGRIK2
- Genetic
- Lead sponsor
- UniQure Biopharma B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more
- Conditions
- Anorexia Nervosa
- Interventions
- Narrative Medicine (NM) Workshop Series
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 16 Years to 25 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Atopic Dermatitis, Psoriasis
- Interventions
- Vitamin D3, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- San Diego, California • Denver, Colorado • Portland, Oregon
- Conditions
- Lymphoma
- Interventions
- denileukin diftitox, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, protein expression analysis, flow cytometry, laboratory biomarker analysis
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Breast Cancer
- Interventions
- Not listed
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan